Navigation

Hypercholesterolaemia - ezetimibe: costing statement

A costing statement has been produced by NICE to provide an implementation tool to estimate the financial impact to the NHS of implementing Technology Appraisal 132 ? Hypercholesterolaemia (Ezetimibe).

The costing statement focuses on the financial impact of therecommendations that require most change in resources to implement in England. The statement has been prepared in consultation with guideline development group, and other clinicians working in this area and has been approved for publication by the Institute.It should be noted that the cost and activity assessments in the report are estimates based on a number of assumptions. These assessments provide an indication of the likely impact of the principal recommendations and are not absolute figures.

The Institute would welcome feedback from users to inform the development of future templates. Please email your comments to costing@nice.org.uk

This page was last updated: 01 January 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.